# Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health

> **NCT05724472** · PHASE1 · COMPLETED · sponsor: **International AIDS Vaccine Initiative** · enrollment: 36 (actual)

## Conditions studied

- Ebola Sudan Virus Disease

## Interventions

- **DRUG:** rVSV∆G-SEBOV-GP Vaccine or Placebo

## Key facts

- **NCT ID:** NCT05724472
- **Lead sponsor:** International AIDS Vaccine Initiative
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-19
- **Primary completion:** 2024-01-09
- **Final completion:** 2024-01-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05724472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05724472, "Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05724472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*